The United States will impose a 100 per cent tariff on imports of branded or patented pharmaceutical products from October 1, unless a pharmaceutical company is building a manufacturing plant in the US.
Some leading Australian experts in medicine, autism research and obstetrics say the US president's claims are "a misreading of science," or at worst, "a misuse". Here's why.